Pyxis Oncology, Inc. (PYXS)
Largest Insider Buys in Sector
PYXS Stock Price History Chart
PYXS Stock Performance
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates …
Insider Activity of Pyxis Oncology, Inc.
Over the last 12 months, insiders at Pyxis Oncology, Inc. have bought $0 and sold $0 worth of Pyxis Oncology, Inc. stock.
On average, over the past 5 years, insiders at Pyxis Oncology, Inc. have bought $5.86M and sold $2.7M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,000 shares for transaction amount of $14,960 was made by Connealy Pamela Ann (CFO and COO) on 2023‑09‑28.
List of Insider Buy and Sell Transactions, Pyxis Oncology, Inc.
| 2023-09-28 | CFO and COO | 8,000 0.0167% | $1.87 | $14,960 | +78.43% | |||
| 2023-09-27 | CFO and COO | 6,426 0.0147% | $1.85 | $11,868 | +97.55% | |||
| 2023-09-27 | Chief Accounting Officer | 2,500 0.0058% | $1.87 | $4,675 | +97.55% | |||
| 2023-09-25 | CFO and COO | 12,000 0.0257% | $1.67 | $20,044 | +103.93% | |||
| 2023-09-25 | Chief Accounting Officer | 5,000 0.0113% | $1.77 | $8,850 | +103.93% | |||
| 2023-09-22 | CFO and COO | 5,000 0.0124% | $1.74 | $8,695 | +126.88% | |||
| 2023-09-22 | Chief Accounting Officer | 2,500 0.0062% | $1.74 | $4,349 | +126.88% | |||
| 2023-09-18 | Sale | President and CEO | 8,541 0.02% | $2.10 | $17,936 | +76.96% | ||
| 2023-09-14 | Sale | President and CEO | 100 0.0002% | $2.25 | $225 | +64.22% | ||
| 2023-09-13 | Sale | President and CEO | 3,000 0.007% | $2.27 | $6,816 | +59.38% | ||
| 2023-09-12 | Sale | President and CEO | 4,917 0.0114% | $2.25 | $11,071 | +60.36% | ||
| 2023-09-11 | Sale | President and CEO | 20,000 0.045% | $2.27 | $45,414 | +54.35% | ||
| 2023-03-17 | 10 percent owner | 1.81M 5.1245% | $2.76 | $5M | -10.51% | |||
| 2022-04-21 | Sale | 1.75M 6.1916% | $3.05 | $5.32M | -16.98% | |||
| 2021-12-08 | director | 10,000 0.0316% | $9.39 | $93,885 | -71.08% | |||
| 2021-11-18 | director | 15,700 0.048% | $12.74 | $200,018 | -78.75% | |||
| 2021-10-13 | director | 312,500 1.3218% | $16.00 | $5M | -70.72% | |||
| 2021-10-13 | 450,000 1.9034% | $16.00 | $7.2M | -70.72% |
Insider Historical Profitability
| PFIZER INC | 10 percent owner | 5952263 10.0168% | $1.90 | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 1118854 1.8829% | $1.90 | 1 | 0 | <0.0001% | |
| Connealy Pamela Ann | CFO and COO | 818532 1.3775% | $1.90 | 4 | 0 | |
| Wadhane Jitendra | Chief Accounting Officer | 226937 0.3819% | $1.90 | 3 | 0 | |
| Civik Thomas | director | 15700 0.0264% | $1.90 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Deep Track Capital Lp | $17.82M | 7.11 | 4.18M | New | +$17.82M | 0.08 | |
| Laurion Capital Management LP | $16.45M | 6.56 | 3.86M | +21.77% | +$2.94M | 0.12 | |
| Balyasny Asset Management Llc | $11.05M | 4.41 | 2.59M | New | +$11.05M | 0.03 | |
| Ikarian Capital LLC | $7.08M | 2.82 | 1.66M | New | +$7.08M | 0.97 | |
| The Vanguard Group | $5.97M | 2.38 | 1.4M | +7.25% | +$403,592.37 | <0.0001 |